


Ask a doctor about a prescription for KYNMOBI 10 mg + 15 mg + 20 mg + 25 mg + 30 mg SUBLINGUAL FILM-COATED TABLETS
Package Leaflet: Information for the Patient
Kynmobi 10 mg sublingual film
Kynmobi 15 mg sublingual film
Kynmobi 20 mg sublingual film
Kynmobi 25 mg sublingual film
Kynmobi 30 mg sublingual film
apomorphine hydrochloride
Kynmobi 10 mg + 15 mg + 20 mg + 25 mg + 30 mg sublingual film
apomorphine hydrochloride
Starter Pack for Treatment Initiation
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
Step-by-Step Instructions
Kynmobi is a medication that is placed under the tongue (sublingual film), which contains the active ingredient apomorphine hydrochloride. It is used, as needed, with other medications for Parkinson's disease taken orally (through the mouth), to reduce the time in "OFF" periods: periods during the day when your symptoms of the disease worsen significantly. Parkinson's disease is a progressive disease of the nervous system, which causes tremors and affects movement.
Do not take Kynmobi
Warnings and Precautions
Consult your doctor or pharmacist before starting to take Kynmobi:
Mouth irritation (oral) is a very common side effect of Kynmobi. Inform your doctor if you develop any of the following signs or symptoms:
These signs and symptoms disappear when treatment with Kynmobi is discontinued.
Inform your doctor if you or your family/caregiver notice that you are developing impulses or desires to behave in an unusual way and cannot resist the impulse, drive, or temptation to carry out certain activities that could harm you or others. These behaviors are called "impulse control disorders" and may include: gambling addiction, overeating or excessive spending, abnormally high sexual desire, or an increase in sexual thoughts or feelings. This type of behavior has been reported in patients taking other medications for Parkinson's disease. Your doctor may need to review your treatments.
Some patients develop symptoms similar to those of addiction, which lead to a compulsive desire to take high doses of Kynmobi and other medications used to treat Parkinson's disease.
Kynmobi may cause neuroleptic malignant syndrome (a disorder of the nervous system that is usually caused by antipsychotics). This is a disorder that causes high fever, confusion, changes in breathing and heart rate, and muscle stiffness.
When you reduce your dose of Kynmobi or discontinue treatment, you may experience withdrawal symptoms such as: lack of interest, anxiety, depression, fatigue, sweating, panic attacks, insomnia, irritability, and pain.
This medication may cause erections of the penis. If these evolve into painful prolonged erections, consult your doctor.
Children and Adolescents
This medication should not be used in children and adolescents under 18 years of age.
Other Medications and Kynmobi
Inform your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication.
Inform your doctor if you are taking:
Taking Kynmobi with Alcohol
Do not drink alcohol while taking this medication.
Pregnancy and Breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Kynmobi is not recommended if you are pregnant. Use an effective contraceptive method if you are of childbearing age.
It is unknown whether Kynmobi is excreted in breast milk. Consult your doctor, who will indicate whether you should interrupt breastfeeding or discontinue Kynmobi, considering the benefit of your treatment and the benefit of breastfeeding for your baby.
Driving and Using Machines
Kynmobi may cause dizziness, drowsiness, or somnolence. Do not drive or operate machinery if you experience any of these side effects.
Kynmobi Contains Metabisulfite
Kynmobi contains metabisulfite, which can rarely cause severe hypersensitivity reactions and bronchospasm, with symptoms such as rash or itching of the skin, difficulty breathing, swelling of the eyelids, face, or lips, and swelling or redness of the tongue. If you experience these side effects, go to the nearest hospital immediately.
This medication contains less than 1 mmol of sodium (23 mg) per sublingual film; this is essentially "sodium-free".
Follow the administration instructions for this medication exactly as indicated by your doctor. If you are unsure, consult your doctor or pharmacist again.
Dose when starting treatment:
A starter pack is available that contains 2 sublingual films of each dose. This pack is usually necessary for your doctor to find the right dose for you.
Your doctor will decide the amount of Kynmobi you should take and how often. You may not need all the sublingual films in the starter pack (for example, if the correct dose for you is 20 mg, then you will not need the 25 mg and 30 mg films).
Maintenance dose:
The recommended dose of this medication will depend on your needs and will be determined by your doctor. Do not take more than one Kynmobi film for an "OFF" episode. You can take Kynmobi up to 5 times a day, but there must be at least 2 hours between doses.
Do not use more than 5 films per day. The maximum daily dose of Kynmobi is 150 mg.
You should place the medication under your tongue and take it whole. Do not cut, chew, or swallow it. See the complete instructions in the "Step-by-Step Instructions"in this package leaflet.
If you take more Kynmobi than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately, call the Toxicology Information Service at 91 562 04 20, indicating the medication and the amount ingested, or go to the hospital immediately. Bring the medication package and this package leaflet with you. This will help the doctor identify what you have taken.
If you stop taking Kynmobi
Do not stop taking Kynmobi unless your doctor tells you to, as your symptoms may worsen.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone will experience them.
Tell your doctor as soon as possibleif you experience any of the following side effects:
Very common: may affect more than 1 in 10 people.
Common: may affect up to 1 in 10 people.
Uncommon: may affect up to 1 in 100 people.
Rare: may affect up to 1 in 1,000 people.
Side effects of unknown frequency (cannot be estimated from available data) are:
Reporting Side Effects
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. You can also report them directly through the Spanish Medication Monitoring System for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date stated on the sachets and carton after EXP. The expiration date is the last day of the month indicated.
Do not store above 25°C. Store in the sachet to protect from light and moisture.
Keep Kynmobi in the sachet until you are ready to take it.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and medications you no longer need at the SIGRE collection point in your pharmacy. If you are unsure, ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Composition ofKynmobi
Appearance of the Product and Container Contents
Kynmobi sublingual film is a rectangular blue to green film with a white printed number indicating the concentration (e.g., "10" means 10 mg).
Kynmobi is available in the following package sizes:
The starter package contains 10 sublingual films with 2 sublingual films of 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg each.
Other packages contain 15 or 30 sublingual films.
Only some package sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Bial - Portela & Cª, S.A.
À Av. da Siderurgia Nacional
4745-457 S. Mamede do Coronado
Portugal
Phone: +351 22 986 61 00
Fax: +351 22 986 61 90
e-mail: [email protected]
Manufacturer
Tesa Labtec GmbH
Heykenaukamp 10
21147 Hamburg
Germany
Local Representative
Laboratorios BIAL, S.A.
C/Alcalá 265, Edificio 2, Planta 2ª
28027 Madrid
Spain
Phone: +34 915624196
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
Portugal, Italy, Germany, France: Kynmobi
Date of the last revision of this leaflet: February 2024.
Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).
Step-by-Step Instructions
Taking Kynmobi | ||
Step 1 | Your doctor has told you to take Kynmobi 10 mg, 15 mg, 20 mg, 25 mg, or 30 mg. Complete steps 2 to 7to take Kynmobi. | |
Step 2 | Drink water.Before taking each Kynmobi, drink water to moisten your mouth. This helps the film dissolve more easily (see Figure A). |
Figure A |
Step 3 | Open the Kynmobi packet. Hold the packet tabs between your thumb and index finger of each hand. Make sure to place your fingers just above the raised points on each tab. Gently pull the tabs to open the packet (see Figure B). |
Figure B |
Step 4 | Remove Kynmobi from the packet. Hold Kynmobi between your fingers by the outer edges and remove it completely from the packet (see Figure C). Kynmobi should be taken whole. Discard the medication if it is broken or missing pieces. Use a new Kynmobi for the dose. |
Figure C |
Step 5 | Place Kynmobi under your tongue. Place Kynmobi under your tongue as far back as possible (see Figure D). Close your mouth. |
Figure D |
Step 6 | Leave Kynmobi in place until it has dissolved completely(see Figure E).
|
Figure E |
Step 7 | Open your mouth to check if Kynmobi has dissolved completely. Kynmobi may take about 3 minutesto dissolve. When Kynmobi has dissolved completely, you can swallow. |
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for KYNMOBI 10 mg + 15 mg + 20 mg + 25 mg + 30 mg SUBLINGUAL FILM-COATED TABLETS – subject to medical assessment and local rules.